The FDA has officially reversed its decades-old stance on menopausal hormone therapy, announcing the removal of black box warnings regarding cardiovascular, dementia, and breast cancer risks. Commissioner Marty Makary stated that the agency now recognizes the treatments offer significant benefits for heart, brain, and bone health. This decision revises the labeling requirements for estrogen and progestogen products to reflect a more nuanced, evidence-based understanding of their safety profile.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.